Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has provided an announcement.
Shanghai Fosun Pharmaceutical announced the formation of a partnership involving its subsidiary Fosun Pingyao and other entities, including Shanghai Fujian, Fosun High Tech, and Fuyao Zhigang, to establish Henan Fujian with a total capital contribution of RMB10 million. This connected transaction, subject to Hong Kong Listing Rules, aims to enhance Fosun’s strategic positioning by creating an associated company, reflecting its ongoing efforts to expand its business operations and strengthen its market influence.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. It focuses on the development and distribution of medical products and healthcare services, with a significant market presence in China.
YTD Price Performance: 10.51%
Average Trading Volume: 5,648
Technical Sentiment Signal: Sell
Current Market Cap: $8.08B
For detailed information about 2196 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue